Rhumbline Advisers Evolus, Inc. Transaction History

Rhumbline Advisers

$109 Billion
Q4 2024

A detailed history of Rhumbline Advisers transactions in Evolus, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 80,149 shares of EOLS stock, worth $1.17 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

80,149

Previous 78,387 2.25%

Holding current value

$1.17 Million

Previous $1.27 Million 30.34%

% of portfolio

0.0%

Previous 0.0%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2024 Jan 30, 2025	BUY	$10.84 - $17.45 $19,100 - $30,746	1,762 Added 2.25%	80,149 $884,000
Q3 2024 Nov 12, 2024	SELL	$10.66 - $17.48 $32,534 - $53,348	-3,052 Reduced 3.75%	78,387 $1.27 Million
Q2 2024 Aug 01, 2024	BUY	$10.45 - $13.76 $182,268 - $240,001	17,442 Added 27.25%	81,439 $883,000
Q1 2024 May 09, 2024	SELL	$9.99 - $14.91 $51,438 - $76,771	-5,149 Reduced 7.45%	63,997 $895,000
Q4 2023 Feb 08, 2024	BUY	$7.6 - $10.53 $40,356 - $55,914	5,310 Added 8.32%	69,146 $728,000
Q3 2023 Nov 09, 2023	BUY	$7.15 - $10.2 $4,719 - $6,731	660 Added 1.04%	63,836 $583,000
Q2 2023 Aug 08, 2023	BUY	$7.23 - $10.52 $54,629 - $79,489	7,556 Added 13.59%	63,176 $459,000
Q1 2023 May 11, 2023	BUY	$7.81 - $11.05 $9,215 - $13,039	1,180 Added 2.17%	55,620 $471,000
Q4 2022 Feb 14, 2023	BUY	$6.52 - $8.95 $13,372 - $18,356	2,051 Added 3.91%	54,440 $409,000
Q3 2022 Nov 10, 2022	BUY	$7.76 - $13.72 $36,751 - $64,977	4,736 Added 9.94%	52,389 $422,000
Q2 2022 Aug 11, 2022	BUY	$10.22 - $13.94 $136,907 - $186,740	13,396 Added 39.1%	47,653 $553,000
Q1 2022 May 12, 2022	BUY	$5.22 - $11.78 $18,807 - $42,443	3,603 Added 11.75%	34,257 $384,000
Q4 2021 Feb 10, 2022	BUY	$5.37 - $8.38 $1,643 - $2,564	306 Added 1.01%	30,654 $200,000
Q3 2021 Nov 12, 2021	BUY	$7.36 - $13.67 $10,281 - $19,096	1,397 Added 4.83%	30,348 $231,000
Q2 2021 Aug 05, 2021	BUY	$8.42 - $13.96 $38,496 - $63,825	4,572 Added 18.75%	28,951 $366,000
Q1 2021 May 06, 2021	SELL	$3.2 - $16.51 $2,272 - $11,722	-710 Reduced 2.83%	24,379 $317,000
Q4 2020 Feb 10, 2021	BUY	$2.92 - $4.84 $9,980 - $16,543	3,418 Added 15.77%	25,089 $84,000
Q3 2020 Nov 12, 2020	SELL	$3.03 - $5.48 $12,847 - $23,235	-4,240 Reduced 16.36%	21,671 $85,000
Q2 2020 Aug 13, 2020	BUY	$3.53 - $6.17 $29,433 - $51,445	8,338 Added 47.45%	25,911 $137,000
Q1 2020 May 06, 2020	BUY	$3.53 - $12.21 $3,971 - $13,736	1,125 Added 6.84%	17,573 $73,000
Q4 2019 Feb 05, 2020	BUY	$11.58 - $17.37 $19,118 - $28,677	1,651 Added 11.16%	16,448 $200,000
Q3 2019 Oct 23, 2019	BUY	$13.91 - $19.87 $27,166 - $38,806	1,953 Added 15.21%	14,797 $231,000
Q2 2019 Aug 14, 2019	BUY	$13.19 - $28.36 $26,419 - $56,805	2,003 Added 18.48%	12,844 $188,000
Q1 2019 May 01, 2019	SELL	$12.43 - $28.91 $124 - $289	-10 Reduced 0.09%	10,841 $245,000
Q4 2018 Jan 31, 2019	BUY	$10.57 - $19.29 $114,695 - $209,315	10,851 New	10,851 $129,000

Others Institutions Holding EOLS

# of Institutions

169

Shares Held

48.8M

Call Options Held

57.2K

Put Options Held

5.5K

View Full List

About Evolus, Inc.

Ticker EOLS
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 56,094,800
Market Cap $820M
Description
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults. The company was incorp...

More about EOLS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Account

Rhumbline Advisers Evolus, Inc. Transaction History